Abstract 548P
Background
Midline gliomas H3K27-altered (GLM-H3K27) are a rare and very aggressive oncologic entity. Although the clinical, imaging, and prognostic characteristics are better characterized in childhood, studies of this pathology in the adult population are scarce.
Methods
Demographic, clinical, treatment, and survival characterization of adult patients with GLM-H3K27, followed at an Oncology Hospital between 2012-2022, through a retrospective review of clinical processes. The data cut-off was 31 December 2022.
Results
Cohort consisting of 17 patients, 53% male, mean age at diagnosis 38 years (18-63 years). The mean time from symptomatology to diagnosis was 3.9 months. The most common initial symptoms are related to cranial nerve dysfunction (6), headache (6) or motor defect (3). The most frequent anatomical locations were thalamus and trunk, 41% and 35%, respectively. Surgical samples were mostly obtained by biopsy (58%), the remainder by partial excision. The initial histological diagnosis varied, including grade 2 to 4 gliomas. In 88% of the cases (N=15) it was possible to identify the presence of the H3F3A K27M mutation by immunohistochemistry and/or mutational analysis of the gene, with 2 of the cases the diagnosis was made only by the loss of expression of H3K27me3. Most patients (82%) were treated with radiotherapy and chemotherapy; in 11.7%, isolated radiotherapy was performed, and only palliative care was given in one case. So far, 14 patients (70.1%) have died; 3 are alive and 1 patient was lost to follow-up. The median disease-free survival was 11 months (95%CI 8.6-13.4 months) and the median overall survival was 20 months (95%CI 12-28 months).
Conclusions
Our study highlights the clinical, anatomical and histological heterogeneity of this new and rare entity, particularly in adulthood. We emphasize the importance of the integrated diagnosis of this population, with the expectation that in the future an effective therapeutic approach can be implemented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10